MetaCap

Can-Fite Biopharma (CANF) vs Processa Pharmaceuticals (PCSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Processa Pharmaceuticals is the larger company by market cap ($4.4 million vs $4.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CANF-28.25%PCSA+15.56%
+48%+8%-33%
Oct 8, 20261 yearNov 20, 2026
CANF-24.47%PCSA+2.63%
+30%+1%-28%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CANF versus PCSA key metrics
MetricCANFPCSA
Share price$1.44$1.56
Market cap$4.35M$4.37M
1-day change-2.34%-7.69%
YTD return-64.13%—
1-year return-75.26%—
5-year return-99.42%—
EPS (TTM)$-13.23$-68.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$405.00K—
Revenue growth (YoY)-39.91%—
Net income (latest FY)$-9.83M$-13.56M
Operating margin-2456.79%—
Net margin-2426.67%—
52-week high$10.40$8.88
52-week low$1.42$1.04
Distance from 52-week high-86.20%-82.43%
Analyst consensusstrong_buy—
Avg. price target upside+457.49%—
Average volume375.00K79.50K
Shares outstanding3.03M2.80M
Employees512
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Can-Fite Biopharma

CANF stock →

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Processa Pharmaceuticals

PCSA stock →

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

CANF vs PCSA FAQ

Which is bigger, Can-Fite Biopharma or Processa Pharmaceuticals?

Processa Pharmaceuticals (PCSA) is larger, with a market capitalization of $4.37M compared with $4.35M for Can-Fite Biopharma (CANF).

Are Can-Fite Biopharma and Processa Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons